Though a small sample of patients, the evidence must at least pique the interest of the FDA, and some form of acceleration of trials and recruitment would have to be going through regulators minds. More importantly, my opinion is it has to be of interest to bigger pharma to at least spend some $'s to see where it leads, so I can see a partner with a fatter wallet coming in here.
Though a small sample of patients, the evidence must at least...
-
- There are more pages in this discussion • 280 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
